請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60982
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 余佳慧(Chia-Hui Yu) | |
dc.contributor.author | Hsiu-Wei Wu | en |
dc.contributor.author | 吳秀薇 | zh_TW |
dc.date.accessioned | 2021-06-16T10:39:44Z | - |
dc.date.available | 2018-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-13 | |
dc.identifier.citation | 1. Scaldaferri F, Pizzoferrato M, Gerardi V, et al. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 2012;46.
2. Farquhar MG, Palade GE. Junctional complexes in various epithelia. J Cell Biol 1963;17:375-412. 3. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124:3-20. 4. Menard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 2010;3:247-59. 5. Keita AV, Soderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol Motil 2010;22:718-33. 6. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009;27:313-38. 7. Sommer F, Backhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol 2013;11:227-38. 8. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904. 9. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-8. 10. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688-93. 11. Xu X, Xu P, Ma C, et al. Gut microbiota, host health, and polysaccharides. Biotechnol Adv 2013;31:318-37. 12. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59-65. 13. Gershon MD. The enteric nervous system: a second brain. Hosp Pract 1995;34:31-2. 14. Bienenstock J, Collins S. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: psycho-neuroimmunology and the intestinal microbiota: clinical observations and basic mechanisms. Clin Exp Immunol 2010;160:85-91. 15. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011;62:381-96. 16. Knowles CH, Aziz Q. Basic and clinical aspects of gastrointestinal pain. Pain 2009;141:191-209. 62 17. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009;136:2003-14. 18. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol 2005;20:332-9. 19. Filaretova L. The hypothalamic-pituitary-adrenocortical system: Hormonal brain-gut interaction and gastroprotection. Auton Neurosci 2006;125:86-93. 20. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011;62:591-9. 21. Soderholm JD, Perdue MH. Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol 2001;280:G7-G13. 22. Cameron HL, Perdue MH. Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2. J Pharmacol Exp Ther 2005;314:214-20. 23. Santos J, Benjamin M, Yang PC, et al. Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. Am J Physiol Gastrointest Liver Physiol 2000;278:G847-54. 24. Santos J, Yang PC, Soderholm JD, et al. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 2001;48:630-6. 25. Hong S, Fan J, Kemmerer ES, et al. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat. Gut 2009;58:202-10. 26. Bradesi S, Schwetz I, Ennes HS, et al. Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 2005;289:3. 27. Larauche M, Bradesi S, Million M, et al. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol 2008;294:28. 28. Moloney RD, O'Leary OF, Felice D, et al. Early-life stress induces visceral hypersensitivity in mice. Neurosci Lett 2012;512:99-102. 29. Barreau F, Cartier C, Leveque M, et al. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay. J 63 Physiol 2007;580:347-56. 30. Chung EK, Zhang X, Li Z, et al. Neonatal maternal separation enhances central sensitivity to noxious colorectal distention in rat. Brain Res 2007;11:68-77. 31. Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol 2009;194:31-74. 32. Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology 2011;141:2098-2108 e5. 33. Harris JA. Using c-fos as a neural marker of pain. Brain Res Bull 1998;45:1-8. 34. Cruz CD, Cruz F. The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr Neuropharmacol 2007;5:244-52. 35. Carrasquillo Y, Gereau RWt. Activation of the extracellular signal-regulated kinase in the amygdala modulates pain perception. J Neurosci 2007;27:1543-51. 36. Gao YJ, Ji RR. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? Open Pain J 2009;2:11-17. 37. Zhang XJ, Li Z, Chung EK, et al. Activation of extracellular signal-regulated protein kinase is associated with colorectal distension-induced spinal and supraspinal neuronal response and neonatal maternal separation-induced visceral hyperalgesia in rats. J Mol Neurosci 2009;37:274-87. 38. Grundy D. Neuroanatomy of visceral nociception: vagal and splanchnic afferent. Gut 2002;51:i2-5. 39. Blackshaw LA, Brierley SM, Hughes PA. TRP channels: new targets for visceral pain. Gut 2010;59:126-35. 40. Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell 2009;139:267-84. 41. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474. 42. Heinricher MM, Tavares I, Leith JL, et al. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res Rev 2009;60:214-25. 43. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel 64 disorders and functional abdominal pain. Gut 1999;45:II43-7. 44. Lu CL, Chen CY, Lang HC, et al. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment Pharmacol Ther 2003;18:1159-69. 45. Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012;46:356-66. 46. Thompson WG. The road to rome. Gastroenterology 2006;130:1552-6. 47. Dorn SD, Morris CB, Hu Y, et al. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin Gastroenterol 2009;43:214-20. 48. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73. 49. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31. 50. Chitkara DK, van Tilburg MA, Blois-Martin N, et al. Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review. Am J Gastroenterol 2008;103:765-74. 51. Bradford K, Shih W, Videlock EJ, et al. Association between early adverse life events and irritable bowel syndrome. Clin Gastroenterol Hepatol 2012;10:385-90. 52. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122:1771-7. 53. Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004;53:1102-8. 54. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-88. 55. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Bmj 1997;314:779-82. 56. Moss-Morris R, Spence M. To 'lump' or to 'split' the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel 65 syndrome? Psychosom Med 2006;68:463-9. 57. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53:1096-101. 58. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005;129:98-104. 59. Barbara G, Cremon C, Pallotti F, et al. Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2009;48. 60. Drossman DA. Mind over matter in the postinfective irritable bowel. Gut 1999;44:306-7. 61. King T. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Clin Nutr 1996;15:143. 62. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007;17:41-7. 63. Chen J, Zhang Y, Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 2012;12:12-91. 64. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52. 65. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987;92:1885-93. 66. Kellow JE, Phillips SF, Miller LJ, et al. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988;29:1236-43. 67. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 2009;403:47-55. 68. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-57. 69. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425-34. 70. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37. 71. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, 66 placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34. 72. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66. 73. Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid 2012;6. 74. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11. 75. van der Veek PP, van den Berg M, de Kroon YE, et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-6. 76. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20. 77. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51. 78. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97-105. 79. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. 80. Martinez C, Gonzalez-Castro A, Vicario M, et al. Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver 2012;6:305-15. 81. Ghoshal UC, Shukla R, Ghoshal U, et al. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;151085:22. 82. Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome. Gastroenterology 2011;141:2098-2108. 83. Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923-9. 67 84. Hong S, Zheng G, Wu X, et al. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology 2011;140:627-637. 85. Stengel A, Tache Y. Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med 2010;235:1168-78. 86. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53:958-64. 87. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008;57:50-8. 88. Santos J, Saunders PR, Hanssen NP, et al. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol 1999;277:G391-9. 89. Tache Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol Motil 2004;1:137-42. 90. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007;56:203-9. 91. Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut. Biochim Biophys Acta 2012;1:85-92. 92. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. 93. van Diest SA, Stanisor OI, Boeckxstaens GE, et al. Relevance of mast cell-nerve interactions in intestinal nociception. Biochim Biophys Acta 2012;1:74-84. 94. Jacob C, Yang PC, Darmoul D, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem 2005;280:31936-48. 95. Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 2010;189:111-26. 96. Leon A, Buriani A, Dal Toso R, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci U S A 1994;91:3739-43. 97. Ernsberger U. Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue 68 Res 2009;336:349-84. 98. Barreau F, Cartier C, Ferrier L, et al. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. Gastroenterology 2004;127:524-34. 99. Willot S, Gauthier C, Patey N, et al. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:734-9. 100. Bohn L, Storsrud S, Tornblom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013;108:634-41. 101. Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med 2006;84:544-50. 102. Rehfeld JF, Bungaard JR, Friis-Hansen L, et al. On the tissue-specific processing of procholecystokinin in the brain and gut--a short review. J Physiol Pharmacol 2003;4:73-9. 103. Liddle RA. Cholecystokinin cells. Annu Rev Physiol 1997;59:221-42. 104. Dockray GJ. Cholecystokinin and gut-brain signalling. Regul Pept 2009;155:6-10. 105. Varga G, Balint A, Burghardt B, et al. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol 2004;141:1275-84. 106. Noble F, Wank SA, Crawley JN, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745-81. 107. Ghilardi JR, Allen CJ, Vigna SR, et al. Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci 1992;12:4854-66. 108. Wiesenfeld-Hallin Z, Xu XJ, Hokfelt T. The role of spinal cholecystokinin in chronic pain states. Pharmacol Toxicol 2002;91:398-403. 109. Rivat C, Becker C, Blugeot A, et al. Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain 2010;150:358-68. 110. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004;92:1982-9. 69 111. Zhang H, Yan Y, Shi R, et al. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008;78:72-6. 112. Van Der Veek PP, Biemond I, Masclee AA. Proximal and distal gut hormone secretion in irritable bowel syndrome. Scand J Gastroenterol 2006;41:170-7. 113. Cremonini F, Camilleri M, McKinzie S, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100:652-63. 114. Dizdar V, Spiller R, Singh G, et al. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2010;31:883-91. 115. Gay J, More J, Bueno L, et al. CCK-induced Fos expression in brain stem is enhanced after intestinal nematode infection in rats. Brain Res 2002;942:124-7. 116. Juanola C, Giralt M, Jimenez M, et al. Mucosal mast cells are involved in CCK disruption of MMC in the rat intestine. Am J Physiol 1998;275:G63-7. 117. Qin HY, Wu JC, Tong XD, et al. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol 2011;46:164-74. 118. Akiho H, Deng Y, Blennerhassett P, et al. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 2005;129:131-41. 119. Faubert G. Immune response to Giardia duodenalis. Clin Microbiol Rev 2000;13:35-54. 120. Monis PT, Caccio SM, Thompson RC. Variation in Giardia: towards a taxonomic revision of the genus. Trends Parasitol 2009;25:93-100. 121. Roxstrom-Lindquist K, Palm D, Reiner D, et al. Giardia immunity--an update. Trends Parasitol 2006;22:26-31. 122. Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev 2001;14:114-28. 123. Lai CC, Wu FT, Ji DD, et al. Gastroenteritis in a Taipei emergency department: aetiology and risk factors. Clin Microbiol Infect 2011;17:1071-7. 124. Eckmann L. Mucosal defences against Giardia. Parasite Immunol 2003;25:259-70. 70 125. Langford TD, Housley MP, Boes M, et al. Central importance of immunoglobulin A in host defense against Giardia spp. Infect Immun 2002;70:11-8. 126. Cotton JA, Beatty JK, Buret AG. Host parasite interactions and pathophysiology in Giardia infections. Int J Parasitol 2011;41:925-33. 127. Tandon BN, Tandon RK, Satpathy BK, et al. Mechanism of malabsorption in giardiasis: a study of bacterial flora and bile salt deconjugation in upper jejunum. Gut 1977;18:176-81. 128. Jimenez JC, Fontaine J, Grzych JM, et al. Systemic and mucosal responses to oral administration of excretory and secretory antigens from Giardia intestinalis. Clin Diagn Lab Immunol 2004;11:152-60. 129. D'Anchino M, Orlando D, De Feudis L. Giardia lamblia infections become clinically evident by eliciting symptoms of irritable bowel syndrome. J Infect 2002;45:169-72. 130. Nygard K, Schimmer B, Sobstad O, et al. A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. BMC Public Health 2006;6:141. 131. Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect 2007;55:524-30. 132. Robertson LJ, Hanevik K, Escobedo AA, et al. Giardiasis--why do the symptoms sometimes never stop? Trends Parasitol 2010;26:75-82. 133. Malin SA, Davis BM, Molliver DC. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat Protoc 2007;2:152-60. 134. Tanaka T, Shinoda M, Feng B, et al. Modulation of visceral hypersensitivity by glial cell line-derived neurotrophic factor family receptor α-3 in colorectal afferents. Am J Physiol Gastrointest Liver Physiol 2011;300:30. 135. Cenac N, Altier C, Motta JP, et al. Potentiation of TRPV4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity. Gut 2010;59:481-8. 136. Tan LL, Bornstein JC, Anderson CR. Distinct chemical classes of medium-sized transient receptor potential channel vanilloid 1-immunoreactive dorsal root ganglion neurons innervate the adult mouse jejunum and colon. Neuroscience 2008;156:334-43. 137. Niederau C, Faber S, Karaus M. Cholecystokinin's role in regulation of colonic motility in health and in irritable bowel syndrome. 71 Gastroenterology 1992;102:1889-98. 138. Sabate JM, Gorbatchef C, Flourie B, et al. Cholecystokinin octapeptide increases rectal sensitivity to pain in healthy subjects. Neurogastroenterol Motil 2002;14:689-95. 139. Rettenbacher M, Reubi JC. Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol 2001;364:291-304. 140. Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499-506. 141. Arizono N, Matsuda S, Hattori T, et al. Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Similarities of distances between neural processes and mast cells, eosinophils, or plasma cells in the jejunal lamina propria. Lab Invest 1990;62:626-34. 142. Blennerhassett MG, Tomioka M, Bienenstock J. Formation of contacts between mast cells and sympathetic neurons in vitro. Cell Tissue Res 1991;265:121-8. 143. Li E, Zhao A, Shea-Donohue T, et al. Mast cell-mediated changes in smooth muscle contractility during mouse giardiasis. Infect Immun 2007;75:4514-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/60982 | - |
dc.description.abstract | 背景與目的:
腸躁症是一種腸胃道功能性失調疾病,特徵是長期反覆性腹痛伴隨排便習慣改變,卻沒有結構上的損傷和病原體的發現。目前腸胃道醫學界對腸躁症的病理機制尚不清楚,大部分的研究是在病人身上,而無公認之動物模式。腸躁症的症狀可能會在生活壓力事件和病原感染導致腸胃炎之後出現。病原感染後出現腸躁症症狀,特稱為後感染性腸躁症,最近在挪威的研究中顯示40-80% 受到一種寄生蟲─梨形蟲感染後的病人會發展成腸躁症。先前動物實驗顯示精神壓力會增加腹痛和腸道屏障功能降低。本研究目的是利用梨形蟲感染後結合避水壓力以雙重因子刺激以建立腸躁症的小鼠模式,評估其腹痛和對腸道屏障功能的影響,並研究其致病機制。 材料與方法: 小鼠給予灌食梨形蟲 (Giardia lamblia) 的滋養體並且計數在小腸中滋養體的數目來確認感染情形。未感染組給予PBS灌食。梨形蟲定殖在小腸中數目的高峰期在感染後第4-7天,定義為「感染期」;而在兩星期後排除體外,因此定義第21-49為「後排除期」。接著進一步在後排除期中第35天進行為期十天的避水壓力 (water avoidance stress, WAS) 或無處理(non-handled, NH)。評估「感染期」與「後排除期」的腸道屏障功能與腹痛敏感程度,並探討相關分子在腸道與背根神經節中的表現。 結果: G. lamblia「感染期」之高峰在第4-7天,小腸定殖之滋養體數目最高且有屏障失能及總細菌量上升的現象;大腸則沒有影響。在「後排除期」中利用結直腸撐張刺激觀察腹部動器反應,發現感染後排除之單一因子會引起痛覺閾值降低,也就是有痛覺異常(allodynia)的現象;而單一精神壓力因子下,則有痛覺過度(hyperalgesia)的現象。在雙重因子下會產生協同效應,使兩種現象都發生。在腸 III 道屏障功能方面,腸道大分子物質通透性和黏膜層緊密連結occludin的片斷化在小腸中的G. lamblia 組別(WAS和NH)相較於個別感染組皆有增加,且在雙重因子下會使occludin片斷化更加明顯;在大腸則都沒有變化。利用螢光原位雜合技術和抗生素阻抗試驗來定位和量化腸道內吞細菌,發現小腸和大腸在G. lamblia 組別皆有細菌入侵腸組織的現象,且雙重因子對細菌入侵的影響更大。利用西方轉漬法測定腸組織與背根神經節中與腸道神經敏感化相關分子:CCK, CCK-1R (AR), CCK-2R (BR) 以及mast cell tryptase的表現。發現大腸組織之CCK在單一精神壓力、G. lamblia 後排除以及雙重因子的組別,表現量皆有明顯上升;而小腸之CCK-1R表現量在單一因子與雙重因子下表現量上升,且G. lamblia 後排除可以強化精神壓力的表現。小腸和大腸組織之CCK-2R則各組之間都沒有變化。此外,分析小腸和大腸的mast cell tryptase表現量發現G. lamblia 組別都有表現量上升,且在大腸中G. lamblia 後排除會強化精神壓力的影響。最後, CCK、CCK-1R、 CCK-2R在背根神經節中的表現量在各組之間則都沒有變化。 結論: 本實驗 G.lamblia 後排除附加慢性避水壓力的動物模式中有腹痛敏感化、腸道屏障失能以及腸道共生菌叢入侵組織等類似腸躁症的病理現象。而腸組織中CCK、CCK-1R 以及mast cell tryptase 表現量的改變可能參與其中的機制。 | zh_TW |
dc.description.abstract | Backgrounds and Aims:
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits without macroscopic abnormality and presence of pathogen. The pathogenesis of IBS is still unclear and most studies are based on patient samples while animal models are not widely recognized. Symptoms of IBS may begin following stressful events or infectious gastroenteritis termed post-infectious (PI) IBS. A recent study in Norway showed that 40-80 % of patients developed IBS symptoms after a parasite Giardia infection. Previous animal studies have shown that psychological stress increases abdominal pain and intestinal barrier disruption. The aim is to establish a IBS model using post-giardiasis combined with water avoidance stress (WAS) to evaluate abdominal pain and gut barrier function. Materials and Methods: Mice were inoculated with Giardia lamblia trophozoites, and the trophozoites in the small intestine were enumerated. The number of colonized Giardia peaked on day 4-7 which was termed “colonization phase”; the parasites were cleared by day 14, and therefore, day 21-49 was denoted “post-clearance phase”. Further water avoidance stress (WAS) or nonhandled (NH) protocols were performed post-giardiasis on PI day 35. Gut barrier function and visceral hypersensitivity are experimented in “colonization V phase” and “post-clearance phase”. Besides, pain-related molecules expression in intestines and dorsal root ganglia (DRG) are analyzed. Results: Intestinal colonization of Giardia trophozoites peaked on day 4-7 and increased macromolecular permeability and tight junction occludin cleavage was seen along with commensal bacterial overgrowth. During the post-clearance phase, increased visceral motor response (VMR) was observed after low-volume colorectal distension, suggesting that post-infection alone triggers allodynia. On the other hand, increased VMR by high-volume distension was noted after WAS, indicating stress alone caused hyperalgesia. Dual factors caused synergistic effects of hyperalgesia and allodynia. Moreover, small intestinal tight junction disruption and increased epithelial permeability were seen in post-giardiasis with or without stress and augmented by dual factors of post-infection and stress. Fluorescence in situ hybridization and gentamycin resistance assay revealed the presence of bacteria in lamina propria and increased endocytosed bacteria in mucosal cells in mice post-giardiasis, which was potentiated by stress. Furthermore, the expression of pain-related molecules including CCK, CCK-1R (AR), CCK-2R (BR) and mast cell tryptase in intestine and dorsal root ganglia were analyzed by Western blotting. In both single and dual factors treated mice, we found increased CCK expression in large intestine and increased CCK-1R VI expression in small intestine, while post-giardiasis augmented the stress effect. Intestinal CCK-2R levels did not change among group. The levels of mast cell tryptase increased in both small and large intestine in post-giardiasis plus stress. The CCK, CCK-1R and CCK-2R levels in dorsal root ganglia were comparable among groups. Conclusion: Post-infection combined with stress caused visceral hypersensitivity, intestinal barrier dysfunction and commensal bacteria invasion. Intestinal CCK, CCK-1R and mast cell tryptase may be involved in the mechanisms of the IBS-like pathology. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T10:39:44Z (GMT). No. of bitstreams: 1 ntu-102-R00441004-1.pdf: 7142913 bytes, checksum: 59d1e698759295c3acf27be1b3bef077 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 致謝...................................................................................................................................I
摘要..................................................................................................................................II 英文摘要........................................................................................................................IV 圖目錄............................................................................................................................XI 表目錄............................................................................................................................XI 附錄.............................................................................................................................XIII 一、前言...........................................................................................................................1 1. 腸道屏障功能 (barrier function) 和共生細菌 (commensal bacteria)...................1 1.1. 物理性、化學性和免疫性屏障.......................................................................1 1.2. 腸道共生菌叢...................................................................................................3 2. 腦腸軸 (brain-gut axis, BGA) 和腦腸菌軸 (brain-gut-microbiota axis, BGMA).4 3. 精神壓力 (psychological stress) 對腸道功能的影響............................................4 4. 內臟痛覺傳遞 (visceral pain pathway)....................................................................6 4.1. 內臟高敏感性 (visceral hypersensitivity)........................................................6 4.2. 上行痛覺調控路徑 (ascending visceral pain pathway)...................................6 4.3. 下行痛覺調控路徑 (descending visceral pain pathway).................................7 5. 腸躁症 (irritable bowel symdrom)...........................................................................7 5.1. 流行病學研究...................................................................................................7 5.2. 危險因子探討...................................................................................................8 5.2.1. 精神壓力...................................................................................................8 5.2.2. 腸胃道感染和後感染腸躁症 (post infectious irritable bowel, PI-IBS) .....................................................................................................9 5.3. 過去臨床研究和機制探討...............................................................................9 VIII 5.3.1. 血清素 (serotonin)..................................................................................10 5.4. 最新臨床研究和機制探討.............................................................................11 5.4.1. 低程度發炎 (low grade inflammation) ...............................................11 5.4.2. 腸道屏障和共生菌叢失衡 (gut barrier dysfunction and dysbiosis) ..11 5.4.3.下視丘─腦下垂體─腎上腺皮質軸與腎上腺皮質酮 (hypothalamic- pituitary-adrenal axis and corticosterone) ...............................................12 5.4.4.肥大細胞 (mast cells) cv12 5.4.5.膽囊收縮素─胰泌素 (Cholecystokinin-Pancreozymin, CCK-PZ)13 5.5. 動物模式之缺乏.............................................................................................14 6. 梨形蟲 (Giardia lamblia).......................................................................................15 6.1. 梨形蟲分類與自然史.....................................................................................15 6.2. 梨形蟲感染引發腸道病變.............................................................................16 6.3. 梨形蟲感染與 PI-IBS 的關係......................................................................17 7. 研究目的.................................................................................................................17 二.材料與方法................................................................................................................18 1. 實驗動物.................................................................................................................18 2. 實驗寄生蟲.............................................................................................................18 3. 動物精神壓力模式.................................................................................................19 4. 實驗動物分組與流程.............................................................................................19 5. 組織處理與實驗分析.............................................................................................20 5.1. 梨形蟲滋養體 (Giardia lamblia trophozoites) 計數....................................20 5.2. 小鼠體重 (body weight) 分析.......................................................................21 5.3. 小鼠血清中腎上腺皮質酮 (corticosterone) 測定........................................21 5.4. 腸道組織大分子通透性(macromolecular permeability)測定..................22 5.4.1.Ussing chamber system............................................................................22 IX 5.4.2.大分子通透性(macromolecular permeability)分析...........................22 5.5. 腸道細菌分析.................................................................................................22 5.5.1.腸段總細菌量 (gut-associated bacteria) 分析.......................................23 5.5.2.腸道黏膜細胞內吞細菌分析 (mucosal endocytosed bacteria assay)....23 5.6. 內臟動器反應(visceromotor response, VMR)分析..................................25 5.7. 背根神經節 (dorsal root ganglion) 的分離..................................................26 5.8. 組織切片與染色.............................................................................................27 5.8.1.石蠟包埋檢體製備....................................................................................27 5.8.2.螢光原位雜合 (fluorescence in situ hybridization, FISH).......................27 5.9.西方轉漬法 (western blotting)...........................................................................28 5.9.1.腸道黏膜層蛋白質萃取............................................................................28 5.9.2.蛋白質定量................................................................................................28 5.9.3.蛋白質電泳................................................................................................29 5.9.4.蛋白質分析................................................................................................29 5.10.統計方法...........................................................................................................31 三.實驗結果....................................................................................................................32 1. G. lamblia之感染與排除時間點.............................................................................32 2. G. lamblia「感染期」對腸道屏障與細菌量之影響.............................................32 2.1. 腸道大分子通透性.........................................................................................32 2.2. 黏膜層緊密連結 occludin 表現...................................................................32 2.3. 腸道總細菌量.................................................................................................33 3. G. lamblia「後排除期」附加避水壓力對小鼠血清中皮質固醇與體重之影響.33 3.1. 血清中腎上腺皮質酮濃度.............................................................................33 3.2. 小鼠體重記錄.................................................................................................34 4. G. lamblia「後排除期」附加避水壓力對腸道功能之影響.................................34 X 4.1. 內臟動器反射.................................................................................................34 4.2. 腸道大分子通透性.........................................................................................35 4.3. 黏膜層緊密連結occludin表現.......................................................................35 4.4. 腸道細菌定位分析.........................................................................................36 4.5. 腸道黏膜入侵細菌之量化.............................................................................36 5. G. lamblia「後排除期」附加避水壓力對腸道與背根神經節中蛋白質分子之改變.............................................................................................................................37 5.1. CCK.................................................................................................................37 5.2. CCK-AR..........................................................................................................38 5.3. CCK-BR..........................................................................................................38 5.4. Mast cell tryptase.............................................................................................38 四、討論.........................................................................................................................39 參考文獻.........................................................................................................................61 | |
dc.language.iso | zh-TW | |
dc.title | 腸道寄生蟲感染小鼠之痛覺和屏障功能變化 | zh_TW |
dc.title | Nociceptive and Barrier changes in Mouse intestines after Parasitic Infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 游偉絢,孫錦虹 | |
dc.subject.keyword | 腸躁症,精神壓力,梨形蟲,內臟高敏感性,腸道屏障, | zh_TW |
dc.subject.keyword | irritable bowel syndrome,psychological stress,Giardia lamblia,visceral hypersensitivity,gut barrier, | en |
dc.relation.page | 71 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 6.98 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。